Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

What is claimed is:

1 (**Cancelled**).

2 (**Currently Amended**). A compound ~~as claimed in claim 1~~ of formula (Ia):



(Ia)

wherein:

R^{10} represents H or C_{1-6} alkyl;
R^{12} represents H, halo, CF_3, cyano, OCF_3, nitro, OR^{13}, SR^{13} , COR^{13} or C_{1-6} alkyl;
R^{13} represents C_{1-6} alkyl or C_{1-4}alkylaryl;
and physiologically functional derivatives thereof.

3 (Cancelled).

4 (**Currently Amended**). A method for ~~the~~ treatment of a human or animal subject **with** ~~suffering from or susceptible to~~ an autoimmune disorder or an inflammatory condition, which ~~method~~ comprises administering to said human or animal subject an effective amount of a compound ~~as claimed in of~~ claim ~~1~~ **2**~~.~~ **wherein:**

the autoimmune disorder or inflammatory condition is selected from:

chronic obstructive pulmonary disease (COPD), asthma, allergen-induced asthmatic reactions, cystic fibrosis, bronchitis, chronic bronchitis, adult respiratory distress syndrome (ARDS), chronic pulmonary inflammation, rhinitis and upper respiratory tract inflammatory disorders (URID), ventilator induced lung injury, silicosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, arthritis, e.g. rheumatoid arthritis, osteoarthritis, infectious arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, Reiter's syndrome, gouty arthritis and prosthetic joint failure, gout, acute synovitis, spondylitis and non-articular inflammatory conditions, herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendonitis, tenosynovitic, fibromyalgic syndrome, inflammatory conditions associated with ligamentous sprain, inflammatory conditions associated with

regional musculoskeletal strain, vascular dementia, thrombosis, atherosclerosis, restenosis, reperfusion injury, plaque calcification, myocarditis, aneurysm, stroke, pulmonary hypertension, left ventricular remodeling or heart failure.

5 (**Cancelled**).

6 (**Currently Amended**). A pharmaceutical composition comprising a compound ~~as claimed in~~ **of** claim ~~1~~ **2, ~~and~~ a** pharmaceutically acceptable carrier**s or diluents ~~therefor~~**, and optionally one or more other therapeutic agents selected from anti-inflammatory agents, NSAIDs, beta adrenergic agents~~,~~ **or** anti-infective agents.

7 (**Currently Amended**). A process for ~~the~~ preparation of compounds of formula ~~(I)~~ **(Ia) ~~as defined in~~ of** claim ~~1~~ **2**, which ~~process~~ comprises:

(A) ~~for the preparation of a compound of formula (I), wherein Z represents a bond and R^1 represents an optionally substituted C_{2-6}alkylaryl or an optionally substituted 5- or 6- membered aryl or heteroaryl,~~ reacting a compound of formula (II):



(II)

wherein:

R^2 **is SO_2R^{10}, wherein R^{10} is as defined in claim 2;**

Q **is phenyl; ~~and~~**

X **is CO_2H ~~are as previously defined for formula (I);~~** and

L represents a leaving group,

with a reagent suitable to introduce ~~the group R^4; or~~ **phenyl optionally substituted by R^{12} ,wherein R^{12} is as defined in claim 2; or**

~~(B) for the preparation of a compound of formula (I) wherein Z represents a bond and R^1 represents an optionally substituted C_{4-12}alkyl, reacting a compound of formula (III):~~



(III)

~~wherein R^2, Q and X are as previously defined for formula (Ia), with a reagent suitable to introduce the group R^4;~~ or

~~(C) for the preparation of a compound of formula (I) wherein Z represents O, S, SO, SO_2, NR^4 or OCR^4R^5, and R^1 represents an optionally substituted C_{4-12}alkyl, reacting~~ a compound of formula (IV):



~~wherein X, R^2 and Q are as previously defined for formula (Ia), and Y represents OH, SH, NR^4H or HCR^4R^5, or with a reagent suitable to introduce the group R^1 followed in the case where Y is SH by optional oxidation of the sulphide to the sulfoxide or the sulfone; or~~

~~(D) for the preparation of a compound of formula (I) wherein Z represents O, S, SO, SO_2, or NR^4, and R^1 represents an optionally substituted C_{2-6}alkylaryl or an optionally substituted 5- or 6- membered aryl or heteroaryl, reacting a compound of formula (IV):~~



~~wherein X, R^2 and Q are as previously defined for formula (I), and Y represents OH, SH or NR^4H, with a reagent suitable to couple to the group R^1, followed in the case where Y is SH by optional oxidation of the sulphide to the sulfoxide or the sulfone; or~~

~~(E) for the preparation of a compound of formula (I) wherein Z represents OCR^4R^5 and R^1 represents an optionally substituted C_{2-6}alkylaryl or an optionally substituted 5- or 6- membered aryl or heteroaryl, reacting a compound of formula (V):~~



~~wherein X, R^2 and Q are as previously defined for formula (I) and L^4 is a suitable leaving group, with a reagent suitable to introduce the group R^1-O; or~~

~~(F) for the preparation of a compound of formula (I) wherein Z represents CR^4R^5O, reacting a compound of formula (IV) :~~



~~**wherein R^2 and Q are as previously defined for formula (I), and Y represents OH, with a reagent suitable to introduce the group $R^1CR^4R^5$; or**~~

~~**(G) for the preparation of a compound of formula (I) wherein Z represents CH_2, reacting a compound of formula (III):**~~



~~**wherein R^2, Q and X are as previously defined for formula (I), with a reagent suitable to introduce the group R^1CH_2;**~~

(H) reacting a compound of formula (VI)



(VI)

or a protected derivative thereof, wherein:

R^1 **is phenyl optionally substituted by R^{12},**
wherein R^{12} us as defined in claim 2,
Z **is a bond**,
Q **is phenyl** and
X is CO_2H ~~**are as previously defined for formula (I),**~~

with a reagent suitable to introduce the group **CO_2H** ~~**R^2 as previously defined for formula (I):**~~ or

(J) carrying out a process selected from processes (A) to ~~**(G)**~~ **(H)** followed by interconversion of one or more functional groups.

8 (**New**). The pharmaceutical composition according to claim 6, wherein:

the anti-inflammatory agents are selected from corticosteroids selected from fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide);

the NSAIDs are selected from sodium cromoglycate, nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, CCR-3 antagonists, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists;

the beta adrenergic agents are selected from salmeterol, salbutamol, formoterol, fenoterol or terbutaline and salts thereof; or

the anti-infective agents are selected from antibiotics or antivirals.